Categories
Marijuana

News of Epidiolex And On Posting Impressive Results, GW Pharmaceuticals Plc (OTCMKTS:GWPRF) Records Weekly Gains of 10% in Stock Price

GW Pharmaceuticals Plc (OTCMKTS:GWPRF) clocked weekly gains of 10% on reporting impressive results and on the news of Epidiolex, a famed drug. It beat the analysts’ expectations and posted better than expected results in the latest quarter.

Impressive sales of Epidiolex

GW Pharmaceuticals posted impressive sales of Epidiolex, a cannabis derived drug. The FDA approved drug is used for the treatment of childhood epilepsy. The company began the sales of Epidiolex in November 2018. The drug contributed sales of $33.5 million of the total sales of $39.5 million of GW Pharmaceuticals.

Phase 3 trial of Epidiolex

GW Pharmaceuticals is pleased to announce positive results of Epidiolex during phase 3 clinical trial. The company conducted phase 3 trial to test the effectiveness of Epidiolex in treating patients suffering from TSC (Tuberous Sclerosis Complex), a severe epilepsy in the childhood.

The drug has shown a considerable reduction in the seizure frequency from the baseline than placebo during the trial. It is the 5th consecutive trial for the drug and reiterates the success. GW Pharmaceuticals plans for the launch of an oral solution – Epidiolex in the five major markets of Europe in the later part of 2019.

The CEO of GW Pharmaceuticals, Justin Gover will be present in Las Vegas on May 15, 2019, Wednesday at the BOA (Bank of America) Merrill Lynch Healthcare Conference.

GW Pharmaceuticals and Greenwich Biosciences, the US subsidiary, will showcase the phase 3 clinical trials of oral solution – Epiodiolex at AAN (American Academy of Neurology) annual conference in Philadelphia on May 4, 2019. The company will present the effectiveness of the drug in treating Dravet Syndrome and Lennox Gastaut syndrome with supporting data.

Justin Gover said the community in the US has well accepted the drug to treat seizures. It is a highly purified cannabidiol sold on prescription.

Precautions

Epidiolex is not recommended for people, who are allergic to any ingredients in this oral solution or CBD. The physician prescribes blood test of the patients to check the health of liver before and after the usage of Epidiolex. The patients need to seek urgent attention of a physician in case of symptoms: fever, nausea, loss of appetite, and itching.

Categories
MMJ

Cannabinoid Medicines Sativex And Epidiolex Transform GW PHARMACEUTICALS (OTCMKTS:GWPRF)

Nashville, TN – GW PHARMACEUTICALS (OTCMKTS:GWPRF) recently reported its fiscal 2014 results highlighted by solid performance of Sativex and great advancements for Epidiolex program. Annual sales of Sativex doubled to GBP 4.4 million in FY14 from GBP 2.2 million during the prior fiscal. The company achieved European approval for this drug last year for treating effects of multiple sclerosis. The Company also advanced its Epidiolex stuides in the U.S. under an “expanded access” program to treat orphan syndromes in the field of childhood epilepsy.

Sativex’s Stellar Performance

GW PHARMACEUTICALS (OTCMKTS:GWPRF) reported GBP 30 million in fiscal 2014 revenue, mostly attributable to commercialization of its cannabinoid drug Sativex. The company reported milestone payments of GBP 24.3 million during FY14 from Otsuka. The payments were received for getting Sativex approved for use in dealing with cancer-related pain.

Japanese drug maker Otsuka has obtained the exclusive rights to develop and commercialize Sativex in the U.S. Following Sativex’s approval and bolstering sales performance, investors are showing interest into the company and are ready to support its development into further markets. The success also helped the company raised GBP 126.3 million or $220 million through two successful offerings on America’s NASDAQ market.

Epidiolex Program

GW PHARMACEUTICALS (OTCMKTS:GWPRF)’s cannabinoid drug Epidiolex is already showing clinical effectiveness in patients suffering from epilepsy. The U.S. FDA also approved physician-led expanded access program and primary data released in October demonstrated significant efficacy and safety profile. More than 400 children and young adults are now authorized for treatment under this program. The company also gets state-based collaboration with the States of Georgia and New York for its Epidiolex clinical trials.

The Epidiolex program has expanded into clinical studies in Europe and the U.S., and is expected to be completed in 2016. Upon successful completion of these trials, British drug maker expects to launch this cannabis-based drug in 2017.

Pin It on Pinterest